International Initiatives on the Assessments of the Value of Medical Technologies
A Health Technology Assessment Council Working Group
-
Special Interest Groups
- Biosimilars
- Clinical Outcome Assessment
- Digital Health
- Health Preference Research
- Medical Devices and Diagnostics
-
Medication Adherence and Persistence
-
Nutrition Economics
- Oncology
- Open Source Models
- Patient-Centered
- Precision Medicine and Advanced Therapies
- Rare Disease
- Real-World Evidence (RWE)
- Statistical Methods in HEOR
-
Task Forces
- Consolidated Health Economic Evaluation Reporting Standards (CHEERS) II
- Joint HTAi - ISPOR Deliberative Processes for HTA
- Machine Learning Methods in HEOR
-
Measurement Comparability Between Modes of Administration of PROMs
- Measuring Patient Preferences for Decision Making
- Performance Outcome (PerfO) Assessments
- Systematic Reviews with Cost and Cost-Effectiveness Outcomes
- Joint ISPE-ISPOR Special Task Force
- Councils & Roundtables
- Global Groups
- Students
-
New Professionals
-
Professional Development Resources
- What is the Impact of GDPR on the HEOR Community
- Good Practices for HTA - What is out there and how do I use it
- ISPOR & AACP Joint Webinar – “Tips for Securing a Post-Doctoral Fellowship”
- You Are Creative: Research is the First Step
- AMCP eDossier System @ FormularyDecisions.com Demo and Practical Application
- Good Practices for a Successful Job Search
- Leveraging The Power Of LinkedIn
- Internships & Fellowships: Career Opportunities for the Future
- My Career Path
- Career Advice Across the Globe
- "My ISPOR Story" - Zeba Khan
- "My ISPOR Story" - Lou Garrison
- Replicate, Regulate, and Redefine: RWE Use Cases in the Next Decade - Session 1
- Replicate, Regulate, and Redefine: RWE Use Cases in the Next Decade - Session 2
- Replicate, Regulate, and Redefine: RWE Use Cases in the Next Decade - Session 3
-
Professional Development Resources
Leadership Group:
Mirella Marlow, MBA, MA, Programme Director, Devices and Diagnostic Systems, Centre for Health Technology Evaluation, The National Institute for Health and Care Excellence (NICE), London, England, United Kingdom
Karolina Socha-Dietrich, Organization for Economic Cooperation and Development (OECD), Copenhagen, Denmark
Adriana Velazquez Berumen, MSc, Senior Advisor and Focal Point on Medical Devices, World Health Organization (WHO), Geneva, Switzerland
Yves Verboven, Director, Market Access & Economic Policies MedTech Europe, Brussels, Belgium
Øyvind Melien, MD, PhD, MSc, Specialist in Clinical Pharmacology and Chair of Secretariat for the Norwegian National System for Managed Introduction of Health Technologies within the Specialist Health Services. Dept. of Medical Devices and Medicinal Products Norwegian Directorate of Health, Oslo, Norway
Claudia Wild, PhD, Director, Ludwig Boltzman Institute for Health Technology Assessment (LBI-HTA), and EUnetHTA, Austria
Reinhard Busse, MPH, University of Berlin, MEDTecHTA, Germany
Giuditta Callea, PhD, University of Bocconi, MedTecHTA, Italy
Jing Xie, PhD, Vice President, Clinical Affairs, Medical Device Innovation Consortium (MDIC), USA
Ralph Ives, Executive Vice President of Global Strategy and Analysis, AdvaMed, USA
Edward L. Trimble, MD, MPH, Director, Center for Global Health, National Cancer Institute, National Institute of Health, USA
Paul C. Pearlman, PhD, Science Policy Advisor/Program Officer, Center for Global Health, National Institutes of Health, National Cancer Institute, USA
TBD, Representatives from Asia-Pacific and Latin America
Objective:
Provide global harmonization and consistency in utilizing and adapting health technology assessment as a supportive tool to inform decisions in the lifecycle of medical technologies to the benefit of the patients, health systems, and society including the value of other tools and initiatives on novel value frameworks to inform decisions and meet the policy objectives.